Balancing Treatment Intensity, Quality of Life, and Biomarker-Driven Approaches in Advanced GI Cancers
Panelists discuss how balancing treatment intensity with quality of life remains a critical challenge in advanced gastric cancers (GCs) and how implementing biomarker-driven approaches such as PD-L1 combined positive score (CPS) testing faces practical hurdles in clinical settings. Key considerations include optimizing patient outcomes while managing adverse effects and addressing barriers such as testing accessibility, result turnaround time, and standardization of biomarker interpretation.
- How might these findings shape discussions about the balance between treatment intensity and maintaining patients’ quality of life in advanced GC/gastroesophageal junction cancer/esophageal adenocarcinoma?
- What barriers might exist in applying biomarker-driven approaches, such as PD-L1 CPS, in real-world clinical settings, and how can they be addressed?
Recent Videos
Related Content
Efficacy and Safety of Zolbetuximab in Gastric Cancer
Aiman Waheed, MBBS;Muhammad Numan Saleem, MBBS;Yash Shah, MD;Muhammad Hamza Gul, MBBS, MD;Helai Hussaini, MD;Abdul Baseer Wardak, MBBS
December 6th 2024Article
Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.
